• Citations Per Year
Learn More
The 50-fold human dosage of a physiomedical drug combination (VG I) (Sinupret) and their components (VG II-VG VI) in equivalent quantity, administered 10 times within 80 h, does not lead to unexpected and undesired effects on the parameters: rate of breathing, pulse rate, red blood count. Quick-%-value and the electrolytes calcium, potassium and sodium.(More)
1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024) was tested on acute and chronic toxicity, on teratogenesis and fetotoxicity, on blood pressure and blood flow behaviour, on hypolipemic activity and general pharmacological behaviour in a screening test using 54 parameters. Results warrant further investigation of the potential(More)
Efficacy of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) and its molecule components (metabolites) of structurally similar theophylline esters and of clofibrate as standard was investigated in the artificial hyperlipidaemia of the rat. In accordance with former results etofylline clofibrate(More)
1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) was investigated in acute and chronic toxicity studies, using oral application. In addition studies in reproduction toxicology and safety pharmacology were performed. Under the conditions of the experiments the following important findings were(More)